Kutatási jelek – Signal Engine

• Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis — Glioblastoma
• Study links hypoxia pathway dysregulation to glioblastoma treatment — Glioblastoma
• XPO1 Inhibition May Reprogram Immune Resistance in SCLC: The TRIM21–IRF3–TNFSF15–TREM2 Axis — SCLC
• GICPIdb: an archival repository of multimodal data focusing on pathological images for gastrointestinal cancers — Colorectal cancer
• Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features — Adenoid cystic carcinoma
• New Cancer Treatment Breakthroughs (2026 Update): The Biggest Advances Changing Cancer Care — Pancreatic cancer
• An RNA molecule contributes to therapy resistance of triple negative breast cancer — Breast cancer
• PARP-1 Inhibitors and Their Emerging Role in the Treatment of Lung Cancer — NSCLC
• Scientists discover why cancer drugs don’t work for everyone — Ovarian cancer
• Integrative single-cell and genomic analysis reveals NMB as a driver of metastatic adaptation in esophageal squamous cell carcinoma via metabolic rewiring and immune evasion — Esophageal cancer
• Treatment‑related lymphopenia predicts long‑term survival in locally advanced head and neck cancer: Post‑Hoc analysis of a randomized phase III trial — Head and neck squamous cell carcinoma
• Prognostic significance of immune-inflammatory and nutritional indicators in locoregionally advanced nasopharyngeal carcinoma — Nasopharyngeal carcinoma
• 2026 RISE UP Conference Targets Breast Cancer and Women9s Health Advances — Breast cancer
• Mapping the de-implementation of traditional diagnostic tests in pediatric acute lymphoblastic leukemia — NSCLC
• Decoy Oligonucleotides in Cancer Therapy: Mechanisms, Challenges, and Clinical Potential — Breast cancer
• Frontiers | Editorial: Reviews in gastrointestinal and hepatic pharmacology: 2024 — Cholangiocarcinoma
• New combination therapy shows promise in metastatic pancreatic cancer — Pancreatic cancer
• New drug targets offer potential pathway for pancreatic cancer treatment — Head and neck squamous cell carcinoma
• Frontiers | RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy — Pancreatic cancer
• Impact of time-of-day and timing interval of neoadjuvant immunotherapy and chemotherapy infusions among patients with operable NSCLC using the inverse probability of treatment weighting method: a dual-center, retrospective study — NSCLC